Claudin 18.2 ADC ATG022 同类最佳潜质显著，峰值有望达50 亿美元：公司近期在ASCO GI 大会上公布了ATG022 I/II 期数据：在CLDN18.2 中高表达（IHC 2+/3+ ≥20%，N=23）/低和极低表达（IHC 2+/3+ <20%，N=10）患者中的ORR 分别达到39%/87%，DCR 分别达到30%/50%。考虑到同靶竞品大多仅在CLDN 18.2 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.